Header

UZH-Logo

Maintenance Infos

EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old


Agache, Ioana; Akdis, Cezmi A; Akdis, Mubeccel; Brockow, Knut; Chivato, Tomas; Del Giacco, Stefano; Eiwegger, Thomas; Eyerich, Kilian; Giménez‐Arnau, Ana; Gutermuth, Jan; Guttman‐Yassky, Emma; Maurer, Marcus; Ogg, Graham; Ong, Peck Y; O’Mahony, Liam; Schwarze, Jürgen; Warner, Amena; Werfel, Thomas; Palomares, Oscar; Jutel, Marek (2022). EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. Allergy, 77(1):17-38.

Abstract

Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1 R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.

Keywords: GRADE; chronic spontaneous urticaria; guidelines; omalizumab.

Abstract

Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1 R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.

Keywords: GRADE; chronic spontaneous urticaria; guidelines; omalizumab.

Statistics

Citations

Dimensions.ai Metrics
15 citations in Web of Science®
19 citations in Scopus®
Google Scholar™

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Swiss Institute of Allergy and Asthma Research
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Immunology and Allergy
Life Sciences > Immunology
Uncontrolled Keywords:Immunology, Immunology and Allergy
Language:English
Date:1 January 2022
Deposited On:20 Jan 2022 15:36
Last Modified:26 Feb 2024 02:44
Publisher:Wiley-Blackwell Publishing, Inc.
ISSN:0105-4538
OA Status:Closed
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1111/all.15030
Official URL:https://onlinelibrary.wiley.com/doi/ftr/10.1111/all.15030
PubMed ID:34324716
Full text not available from this repository.